In this diagnostic study, 65 participants undergoing skin biopsy were imaged with a novel cross-modal system. Expert readers used traditional hematoxylin and eosin histopathology to validate skin features identified on cross-modal imaging and to train blinded physician readers; in performance testing, blinded readers scored 96.4% accuracy in feature identification.
In a multicenter study, cross-modal imaging aligned with biopsy-confirmed histopathology and showed high physician reader agreement, supporting its FDA-cleared role in clinical assessment featuring Enspectra Health
